A Study of Fluzoparib±Apatinib Versus Placebo Maintenance Treatment in Patients With Advanced Ovarian Cancer Following Response on First-Line Platinum-Based Chemotherapy
PHASE3
This is a multicenter, randomized, blinded, 3-arm Phase 3 study to evaluate...
Status
Unknown
Location
Cancer Hospital Chinese Academy of Medical Sciences
A Study of Apatinib Combined With Letrozole With or Without Fluzoparib in Estrogen Receptor-Positive, Platinum-Sensitive Recurrent Ovarian Cancer Previously Treated With First-Line PARP Inhibitor
NA
This multicenter, open-label, prospective cohort clinical study enrolled 70...
Status
Terminated
Location
Peking Union Medical College Hospital (PUMCH), Chinese Academy of Medical Sciences